Non-Small Cell Lung Cancer Program

Led by Dr. Stephan Morris, who discovered the ALK oncogene, Insight Genetics has deep knowledge and expertise surrounding both the therapeutic and diagnostic sides of non-small cell lung cancer (NSCLC).


Traditionally, molecular testing has utilized solid tissue samples from patient tumor biopsies. Although taking a tumor biopsy is the standard of practice for initial cancer diagnosis, repeat biopsies are not common practice and are an impractical requirement to assess treatment efficacy and disease monitoring. A number of cutting-edge companies are spearheading technology that allows for the harvesting of nucleic acid (DNA or RNA) from non-invasive samples (e.g. blood draw, urine, etc.). Insight Genetics is dedicating significant Research and Development resources to adapting our molecular assays for solid tumor biopsies to be compatible with liquid biopsies. Through partnerships with non-invasive platform companies, our molecular assays are being utilized with circulating free DNA, and RNA/DNA from circulating tumor cells and exosomes.


Insight Genetics has developed multiple single-gene diagnostic assays that serve to guide treatment decisions. All assays are extremely sensitive, require low sample input, and have quick turnaround times.  We are currently adapting these assays for compatibility with liquid biopsy sample types. 


With recent guidelines from NCCN and CAP-IASLC-AMP calling for testing of multiple actionable biomarkers at once, Insight Genetics continues to build on our portfolio of multiplex panel offerings.  These assays require minimal sample input and offer quick turnaround times.  They are being designed for both solid tumor and liquid biopsy sample types. 


Unfortunately, NSCLC patients undergoing treatment with targeted therapies often develop therapeutic resistance and experience disease progression after an average of 10-12 months. Insight Genetics is dedicated to identifying the molecular mechanisms of resistance using solid and liquid biopsy material to inform subsequent treatment decisions.